Clarity Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2025: 73.99%

Clarity Pharmaceuticals Ltd (CU6) has an Asset Resilience Ratio of 73.99% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Clarity Pharmaceuticals Ltd (CU6) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$189.17 Million

≈ $133.85 Million USD Cash + Short-term Investments

Total Assets

AU$255.67 Million

≈ $180.90 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Clarity Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Clarity Pharmaceuticals Ltd.

Liquid Assets Composition Over Time

This chart breaks down Clarity Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Clarity Pharmaceuticals Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$33.37 Million	13.05%
Short-term Investments	AU$155.80 Million	60.94%
Total Liquid Assets	AU$189.17 Million	73.99%

Asset Resilience Insights

Very High Liquidity: Clarity Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 73.99% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Clarity Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Clarity Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Celldex Therapeutics Inc NASDAQ:CLDX	Biotechnology	81.32%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Savara Inc NASDAQ:SVRA	Biotechnology	68.30%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%

Annual Asset Resilience Ratio for Clarity Pharmaceuticals Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Clarity Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	65.08%	AU$65.84 Million ≈ $46.59 Million	AU$101.17 Million ≈ $71.59 Million	-2.05pp
2024-06-30	67.13%	AU$103.80 Million ≈ $73.45 Million	AU$154.63 Million ≈ $109.41 Million	-9.65pp
2023-06-30	76.78%	AU$59.04 Million ≈ $41.77 Million	AU$76.90 Million ≈ $54.41 Million	+14.67pp
2022-06-30	62.11%	AU$62.00 Million ≈ $43.87 Million	AU$99.82 Million ≈ $70.63 Million	+15.68pp
2021-06-30	46.43%	AU$10.50 Million ≈ $7.43 Million	AU$22.61 Million ≈ $16.00 Million	+35.46pp
2020-06-30	10.97%	AU$1.00 Million ≈ $707.56K	AU$9.12 Million ≈ $6.45 Million	-32.67pp
2019-06-30	43.65%	AU$4.52 Million ≈ $3.20 Million	AU$10.36 Million ≈ $7.33 Million	--

pp = percentage points

About Clarity Pharmaceuticals Ltd

AU:CU6 Australia Biotechnology

Market Cap

$575.47 Million

AU$813.32 Million AUD

Market Cap Rank

#11631 Global

#297 in Australia

Share Price

AU$2.18

Change (1 day)

+3.81%

52-Week Range

AU$1.82 - AU$5.70

All Time High

AU$8.79